Gupta Ramesh K, Tiller John W, Burrows Graham D
Phillip Health Centre, Woden, Canberra, Australia.
Aust N Z J Psychiatry. 2003 Apr;37(2):190-5. doi: 10.1046/j.1440-1614.2003.01169.x.
To review controlled studies of long-term treatment and their side-effects with newer dual action antidepressants following an acute episode of major depression.
A literature review (MedLine) was undertaken and references were selected for their relevance and methodology in describing their contribution to the examination of our objective.
Three dual action antidepressants are identified: venlafaxine, mirtazapine and milnacipran. These are more effective and better tolerated than the older tricyclic antidepressants in the treatment of an acute episode of depression and in the prevention of relapse. They also offer advantages in that they lack autonomic side-effects of the tricyclics. However, sedation, nausea and sexual side-effects may occur with venlafaxine, and weight gain with mirtazapine.
回顾重度抑郁症急性发作后使用新型双重作用抗抑郁药进行长期治疗的对照研究及其副作用。
进行了文献综述(医学在线数据库),并根据其相关性和描述对我们目标研究贡献的方法来选择参考文献。
确定了三种双重作用抗抑郁药:文拉法辛、米氮平和米那普明。在治疗抑郁症急性发作和预防复发方面,这些药物比旧的三环类抗抑郁药更有效且耐受性更好。它们还具有优势,即缺乏三环类药物的自主神经副作用。然而,文拉法辛可能会引起镇静、恶心和性功能副作用,米氮平会导致体重增加。